Skip to main content
Clinical Trials/NCT05758103
NCT05758103
Completed
Not Applicable

Limosilactobacillus Reuteri as an Adjuvant in the Treatment of Peri-implant Mucositis in Total Rehabilitation: an Exploratory Study

Malo Clinic1 site in 1 country32 target enrollmentJanuary 5, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peri-implant Mucositis
Sponsor
Malo Clinic
Enrollment
32
Locations
1
Primary Endpoint
Modified bleeding index
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Mechanical debridement is the traditional method for the treatment of peri-implant mucositis and its success depends on the patient's correct oral hygiene. It is believed that probiotics may help by their ability to modulate the oral biofilm, resulting in anti-inflammatory and anti-bacterial plaque action. The aim of this study is to evaluate the adjuvant effect of the probiotic Limosilactobacillus reuteri in the mechanical treatment of peri-implant mucositis. This study aims to include 32 subjects with implant-supported total rehabilitation and peri-implant mucositis, divided into test and control groups, equally subjected to professional mechanical debridement, with the administration of a daily GUM® PerioBalance® lozenge for 30 days added to the test group. Plaque Index, Bleeding Index and probing pocket depth are evaluated before the intervention (baseline) and at 6 and 10 weeks later.

Registry
clinicaltrials.gov
Start Date
January 5, 2022
End Date
September 18, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Malo Clinic
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • (i) dental implants placed for at least 12 months according to the All-on-4® concept;
  • (ii) removal of the dental prosthesis as part of the conventional implant maintenance protocol;
  • (iii) modified Bleeding Index19 score \>0 in at least one implant in the studied rehabilitation;
  • (iv) implants connected to the prosthesis by means of transepithelial abutments;
  • (v) if there were natural teeth in opposing arch, they were periodontally healthy or had been treated for periodontitis and were on periodontal support with residual pockets ≤5mm;
  • (vi) demonstrated previous compliance with oral hygiene appointments; (vii) read and signed the informed consent.

Exclusion Criteria

  • (i) Peri-implantitis proven clinically (implant mobility, suppuration and/or pocket depth (PD) ≥5mm) and/or radiographically (bone remodeling greater than 2mm in the first year of function20 and mean marginal bone loss greater than 0.2mm for each subsequent year21 in the rehabilitated arch that was intended to be studied);
  • (ii) clinically active peri-implantitis (mobility, suppuration and/or PD ≥5mm) in the opposing arch to the one intended to be studied;
  • (iii) presence of an extra-maxillary/zygomatic implant in the rehabilitated arch that was intended to be studied;
  • (iv) current probiotic supplementation;
  • (v) diabetes mellitus not controlled by medication;
  • (vi) current use of oral hygiene products containing chlorohexidine or essential oils;
  • (vii) special needs individuals who depended on others for their oral hygiene and medication uptake.

Outcomes

Primary Outcomes

Modified bleeding index

Time Frame: baseline, 6 weeks, 10 weeks

Change of the bleeding score on each dental implant from baseline to 6 weeks and from baseline to10 weeks. Modified bleeding index- 0: absence of bleeding; 1: isolated bleeding spots visible; 2: blood forms a confluent red line on margin; 3: heavy or profuse bleeding.

Secondary Outcomes

  • Modified plaque index(baseline, 6 weeks, 10 weeks)
  • Probing pocket depth(baseline, 6 weeks, 10 weeks)

Study Sites (1)

Loading locations...

Similar Trials